drugset / Trial / NCT01197417

Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis

NCT01197417 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of intravenous magnesium in shortening the duration of a pain crisis and to determine the health-related quality of life and short term outcomes of children treated with intravenous magnesium during an acute pain crisis.

Timeline

Start
2010-12
Primary completion
2014-03
Completion
2014-03

Outcome

Missed primary endpoint

paper The median interquartile range (IQR) length of stay was 56.0 (27.0-109.0) hours for magnesium vs 47.0 (24.0-99.0) hours for placebo (P = .24). PMID 26232172 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified 40 mg/kg Intravenous

Indications